LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article: Integrating qualitative interviews in drug development and the use of qualitative evidence in product labelling and health technology assessments: a review.

    Michel, Anne-Sophie / Kamudoni, Paul / Marrel, Alexia / Adiutori, Rocco / Desvignes-Gleizes, Céline / Lanar, Sally / Schache, Peter / Spies, Erica / Park, Josephine

    Frontiers in medicine

    2023  Volume 10, Page(s) 1197529

    Abstract: Objective: Including qualitative research in clinical trial design is an innovative approach to understanding patients' perspective and incorporate the patient's voice in all stages of drug development and evaluation. This review aims to explore current ...

    Abstract Objective: Including qualitative research in clinical trial design is an innovative approach to understanding patients' perspective and incorporate the patient's voice in all stages of drug development and evaluation. This review aims to explore current practices, lessons learned from the literature, as well as how qualitative interviews are considered by health authorities for marketing authorization and reimbursement.
    Methods: A targeted literature review of Medline and Embase databases was conducted in February 2022 to identify publications on qualitative methods embedded in clinical trial of pharmaceutical products. An additional search of guidelines and labeling claims of approved products regarding qualitative research was performed in various sources of grey literature.
    Results: From the 24 publications and nine documents reviewed, we identified the research questions addressed with qualitative methods during clinical trials (e.g., change in quality of life, symptoms assessment, treatment benefit), preferred data collection methods (e.g., interviews), and data collection points (e.g., baseline and exit interviews). Moreover, the data from labels and HTAs demonstrate that qualitative data can play an important role in approval processes.
    Conclusion: The use of in-trial interviews is still emerging and is not yet common practice. Although the industry, scientific community, regulatory agencies and HTAs are showing an increasing interest in the use of evidence generated via in-trial interviews, guidance from regulators and HTAs would be helpful. Developing new methods and technologies to address the common challenges for such interviews is key to progress.
    Language English
    Publishing date 2023-06-20
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2775999-4
    ISSN 2296-858X
    ISSN 2296-858X
    DOI 10.3389/fmed.2023.1197529
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Description of a late miscarriage case at 16 Weeks of Gestation associated with a SARS-CoV-2 infection.

    Michel, Anne-Sophie / De Logiviere, Victoire / Schnuriger, Aurélie / Lefebvre, Mathilde / Maisonneuve, Emeline / Kayem, Gilles

    Journal of gynecology obstetrics and human reproduction

    2021  Volume 50, Issue 3, Page(s) 102064

    Abstract: Background: Data about obstetric complications of maternal infection by SARS-CoV-2 remain sparse.: Case: A 40-year-old pregnant woman, gravida 3 para 1 with no previous obstetric complications, presented a late miscarriage at 16 weeks of gestation on ...

    Abstract Background: Data about obstetric complications of maternal infection by SARS-CoV-2 remain sparse.
    Case: A 40-year-old pregnant woman, gravida 3 para 1 with no previous obstetric complications, presented a late miscarriage at 16 weeks of gestation on day 9 of COVID-19 disease. The results of her nasopharyngeal swab for SARS-CoV-2, tested the same day, were negative, but the placenta was infected by SARS-CoV-2 and serology was positive 11 days later. No other obstetric or infectious cause was found to explain this outcome.
    Conclusion: This case strongly suggests that SARS-CoV-2 may lead to a late miscarriage.
    MeSH term(s) Abortion, Spontaneous/virology ; Adult ; COVID-19/complications ; COVID-19/diagnosis ; COVID-19 Serological Testing ; COVID-19 Testing/methods ; Female ; Fetus/virology ; Gestational Age ; Humans ; Placenta/virology ; Pregnancy ; Pregnancy Complications, Infectious/virology ; Real-Time Polymerase Chain Reaction ; SARS-CoV-2/genetics ; SARS-CoV-2/immunology ; SARS-CoV-2/isolation & purification
    Language English
    Publishing date 2021-01-13
    Publishing country France
    Document type Case Reports
    ISSN 2468-7847
    ISSN (online) 2468-7847
    DOI 10.1016/j.jogoh.2021.102064
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: The Endometrial Immune Profiling May Positively Affect the Management of Recurrent Pregnancy Loss.

    Cheloufi, Meryam / Kazhalawi, Alaa / Pinton, Anne / Rahmati, Mona / Chevrier, Lucie / Prat-Ellenberg, Laura / Michel, Anne-Sophie / Dray, Geraldine / Mekinian, Arsène / Kayem, Gilles / Lédée, Nathalie

    Frontiers in immunology

    2021  Volume 12, Page(s) 656701

    Abstract: Introduction: The endometrial immune profiling is an innovative approach based on the analysis of the local immune reaction occurring in the endometrium at the time of the embryo implantation. By documenting the local immune activation during the period ...

    Abstract Introduction: The endometrial immune profiling is an innovative approach based on the analysis of the local immune reaction occurring in the endometrium at the time of the embryo implantation. By documenting the local immune activation during the period of uterine receptivity, we aim to detect and correct potential imbalances before and at the very beginning of placentation. The main objective of the study was to analyze in women with a history of repeated pregnancy loss (RPL) the association of personalized strategies based on immune dysregulations with live birth rates. The secondary objective was to highlight the main prognostic factors for live births.
    Methods: This is an observational retrospective analysis of 104 patients with RPL, included between January 2012 and December 2019. Inclusion criteria included a spontaneous fertility with at least three miscarriages, an assessment including a three-dimension ultrasound scan, an endometrial biopsy for uterine immune profiling and a follow-up over at least 6 months with personalized care if indicated after the complete assessment. We defined as a success if the patients had a live birth after the suggested plan, as a failure if the patient either did not get pregnant or experienced a new miscarriage after the targeted therapies.
    Results: Uterine immune profiling was the only exploration to be significantly associated with a higher live birth rate (LBR) if a dysregulation was identified and treated accordingly (55% vs 45%, p=0.01). On the contrary, an absence of local dysregulation (resulting in an apparently balanced immune environment) was associated with a higher risk of a new miscarriage, suggesting that the cause inducing RPL still needed to be identified. Independently of age and AMH level, dysregulated immune profile is significatively associated with 3 times higher LBR than a non-deregulated profile (OR=3.4 CI 95%1.27-9.84) or five times in case of an overactive profile treated by immunotherapy (OR=5 CI 95% 1.65-16.5). The usage of ART was significantly associated with lower LBR regardless of the presence of a subfertility factor (p=0.012). Personalization of medical care using natural cycle or simple hormonal stimulation is associated with a significantly higher LBR than personalization including ART treatments regardless of maternal age and AMH level (OR= 2.9 CI 95% 1.03-8.88).
    Conclusion: Our study suggests that some endometrial immune profiles with targeted management of RPL are associated with a higher rate of LBR. ART may be negatively associated with LBR.
    MeSH term(s) Abortion, Habitual/etiology ; Abortion, Habitual/metabolism ; Adult ; Biomarkers ; Biopsy ; Disease Management ; Disease Susceptibility ; Endometrium/immunology ; Endometrium/metabolism ; Endometrium/pathology ; Female ; Humans ; Middle Aged ; Pregnancy ; Pregnancy Outcome ; Prognosis ; Young Adult
    Chemical Substances Biomarkers
    Language English
    Publishing date 2021-03-24
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2021.656701
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Impact of time to local recurrence on the occurrence of metastasis in breast cancer patients treated with neoadjuvant chemotherapy: A random forest survival approach.

    Laas, Enora / Hamy, Anne-Sophie / Michel, Anne-Sophie / Panchbhaya, Nabilah / Faron, Matthieu / Lam, Thanh / Carrez, Sophie / Pierga, Jean-Yves / Rouzier, Roman / Lerebours, Florence / Feron, Jean-Guillaume / Reyal, Fabien

    PloS one

    2019  Volume 14, Issue 1, Page(s) e0208807

    Abstract: Background: We studied the relationship between time to ipsilateral breast tumor recurrence (IBTR) and distant metastasis-free survival (DMFS) in patients with breast cancer treated by neoadjuvant chemotherapy (NAC).: Methods: Between 2002 and 2012, ... ...

    Abstract Background: We studied the relationship between time to ipsilateral breast tumor recurrence (IBTR) and distant metastasis-free survival (DMFS) in patients with breast cancer treated by neoadjuvant chemotherapy (NAC).
    Methods: Between 2002 and 2012, 1199 patients with primary breast cancer were treated with NAC. Clinical, radiological and pathological data were retrieved from medical records. Multivariate analysis was performed with the random survival forest (RSF) method, to evaluate the relationship between time to local recurrence and DMFS.
    Results: Time to IBTR, local recurrence and molecular subtype were the factors most strongly associated with DMFS. In the total population, DMFS increased linearly with recurrence time, up to 50 months. For recurrences after 50 months, DMFS was similar for all times to recurrence. Considering molecular subtypes separately, the threshold was similar for the TNBC subtype (50 months), but appeared to occur later for the luminal and HER2-positive subtypes (75 months).
    Conclusion: A threshold of 50 months seems to differentiate between early and late recurrences and could be used to guide the medical management of local breast tumour recurrences.
    MeSH term(s) Adult ; Breast Neoplasms/drug therapy ; Breast Neoplasms/pathology ; Disease-Free Survival ; Female ; Humans ; Middle Aged ; Multivariate Analysis ; Neoadjuvant Therapy/methods ; Neoplasm Metastasis/drug therapy ; Neoplasm Metastasis/pathology ; Risk Factors ; Time Factors
    Language English
    Publishing date 2019-01-23
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 1932-6203
    ISSN (online) 1932-6203
    DOI 10.1371/journal.pone.0208807
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top